louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02269696: The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients
Official title: The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Breast Cancer
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
First posted: 2014-10-21
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to test the effects of metoprolol on anaesthesia and the need for perioperative analgesics in patients undergoing breast surgery. With 12 months follow-up the incidence of pain and life satisfaction will be evaluated.

Detailed description: The purpose of the study is to test the effects of intraoperative metoprolol on 1) anaesthetic and alagesic use 2) pain during the early postoperative period and 3) the incidence of pain and lide satisfaction up to 12 months after the surgery. Adverse effects will be recorded as safety measures.

Eligibility criteria: Inclusion Criteria:

* Elective breast surgery due to breast cancer
* Voluntary
* BMI ≥ 18 and ≤ 35 kg/m2
* ASA 1-3
* No regular use of beta-blockers or during the last 72 hours
* No contraindications to beta-blockers

Exclusion Criteria:

* Pregnancy or breast feeding
* AV-block, degree II or III
* Untreated cardiac insufficiency
* Sinus bradycardia, heart rate \< 45 / min or symptoms
* Sick sinus syndrome
* Cardiogenic shock
* Severe peripheral vascular disorder
* Systolic blood pressure \< 100 mmHg
* Long PQ-time, \> 0,24 seconds
* Known hypersensitivity to beta-blockers or the ingredients of the drug

Primary outcomes:
measure: Anaesthesia
timeFrame: Intraoperative
measure: Anaesthesia
timeFrame: Intraoperative
measure: Postoperative pain
timeFrame: First 4 postoperative hours
measure: Postoperative pain
timeFrame: First 4 postoperative hours
measure: Postoperative pain
timeFrame: First 4 postoperative hours
measure: Long-term pain
timeFrame: 3 months
measure: Long-term pain
timeFrame: 1 year
Secondary outcomes:
measure: Safety and tolerability
timeFrame: Perioperative
measure: Distribution to the central nervous system
timeFrame: Perioperative
measure: Life satisfaction
timeFrame: 1 year
measure: Anxiety
timeFrame: 1 year
measure: Depression
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04196296: Treatment Seeking for Social Anxiety
Official title: Brief Online Interventions to Facilitate Treatment Seeking for Social Anxiety
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Social Anxiety
Lead sponsor: University of Colorado, Boulder
Sponsor class: OTHER
First posted: 2019-12-12
Enrollment: 919
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study developed and then compared via randomized trial two brief online interventions targeting increasing treatment-seeking behavior in social anxiety.


Eligibility criteria: Inclusion Criteria:

* High social anxiety (score \>30 on Social Phobia Inventory (SPIN) Connor et al., 2000)
* Fluent in English
* Amazon Mechanical Turk HIT approval rate \> 95%
* Amazon Mechanical Turk account listed as US resident

Exclusion Criteria:

* Already enrolled in target treatments (i.e. CBT for social anxiety, using social anxiety self-help book, or participating in online treatment for social anxiety)
* Indicating that they would "never consider" treatment for social anxiety

Primary outcomes:
measure: Treatment seeking motivations: Attitudes toward seeking treatment for social anxiety.
timeFrame: Change from baseline to one-month follow-up
measure: Treatment seeking motivations: Intentions to seek treatment for social anxiety.
timeFrame: Change from baseline to one-month follow-up
measure: Treatment seeking motivations: Perceived behavioral control/confidence regarding seeking treatment for social anxiety.
timeFrame: Change from baseline to one-month follow-up
Secondary outcomes:
measure: Treatment seeking behaviors
timeFrame: One-month follow-up
Other outcomes:
Locations:
city: Boulder
country: United States
facility: University of Colorado Boulder
state: Colorado
Study officials:
References:
Clinical trial NCT00437996: Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial
Official title: Epidural Analgesia During Labour. Impact of Clonidine Addition to Levobupivacaine and Sufentanil
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Normal Pregnancy
Keywords: Labor analgesia - clonidine - epidural
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2007-02-21
Enrollment: 85
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Addition of clonidine to an epidural mixture of local anaesthetic and morphine improves analgesia and reduces the frequency of motor blockade during epidural analgesia. several side effects are possible mostly somnolence and hypotension. Association of continuous clonidine infusion with low concentrations of levobupivacaïne and sufentanil was not studied during labour. The objective of this study is to compare the effectiveness and the side effects of a PCEA with levobupivacaïne 0,0625 % and sufentanil 0.25 microg.ml-1, without addition of clonidine, and with addition of clonidine at a concentrations of 2 microg.ml-1.


Eligibility criteria: Inclusion Criteria:

* Patients of ASA class I or II
* Variable parity
* Aged of 18 years or more
* With a normal pregnancy
* Cervical dilation between 3 and 8 cm)
* Wishing an epidural analgesia
* Normal childbirth
* Giving their written assent
* Affiliated with a social security system
* Must have had an anaesthesia consultation more than 48 hours before inclusion.

Exclusion Criteria:

* Request of the patient
* Failure of epidural analgesia
* Childbirth in the 90 minutes following the induction of analgesia
* Realization of a Caesarean section

Primary outcomes:
measure: Score of quality at the time of the childbirth based on a 4-point scale : motor blockade - no sensation - nonpainful sensation - pain.
Secondary outcomes:
measure: Motor blockade quantification by a score of modified Bromage specific way.
measure: Labor analgesia.
measure: Circulatory parameters(arterial pressure and heart rate will be noticed at 5 - 10 - 15 - 20 - 30 - 60 minutes and every hour until childbirth).
Other outcomes:
Locations:
city: Lyon
country: France
facility: Henri Jacques CLEMENT
city: Lyon
country: France
facility: Anesthesie Reanimation - Gynecologie - Hopital de La Croix Rousse
Study officials:
affiliation: Hospices Civils de Lyon
name: HENRI-JACQUES CLEMENT, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wallet F, Clement HJ, Bouret C, Lopez F, Broisin F, Pignal C, Schoeffler M, Derre E, Charpiat B, Huissoud C, Aubrun F, Viale JP. Effects of a continuous low-dose clonidine epidural regimen on pain, satisfaction and adverse events during labour: a randomized, double-blind, placebo-controlled trial. Eur J Anaesthesiol. 2010 May;27(5):441-7. doi: 10.1097/EJA.0b013e3283365944.
Clinical trial NCT01364116: The Accuracy of Noninvasive and Continuous Hemoglobin Measurement by Pulse CO-Oximetry™ in Children Undergoing Volume Expansion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Continuous Hemoglobin Measurement
Keywords: Pulse CO-Oximetry™
children
noninvasive
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2011-06-02
Enrollment: 46
Sex: ALL
Minimum age (years): 1
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children under 10 years old who were planned to take elective surgery which may cause patients' hemodynamic unstability.

Patients who require intraoperative invasive arterial blood pressure monitoring.

Brief summary: Measuring total hemoglobin(tHb) is a precious step to decide to start or to stop transfusion during operation. The newly developed instrument pulse CO-Cooximetry (Masimo) makes noninvasive monitoring of venous hemoglobin level (SpHb).

The objective of this study

* to compare the simultaneous level of tHb and SpHb during operation and after volume expansion in children
* to assess the accuracy of amount of acute change of SpHb on Masimo and tHb


Eligibility criteria: Inclusion Criteria: children under 10 years old how are diagnosed as

* brain tumor
* intraabdominal tumor
* intrathoracic tumor
* craniosynostosis
* scoliosis

Exclusion Criteria:

* cardiopulmonary disease
* preoperative infection
* genetic disease
* hematologic disease

Primary outcomes:
measure: hemoglobin concentrations from laboratory lab and pulse Co-oximetry
timeFrame: before and after volume expansion (20 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT04914416: Evaluation of OxxyneaGS in Acute Glycemic Regulation on Light Hyperglycemic Subjects
Official title: OxxyneaGS: Single Blinded Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hyperglycemia, Postprandial
Lead sponsor: Fytexia
Sponsor class: INDUSTRY
First posted: 2021-06-04
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to evaluate and select the best combination of polyphenol and white kidney bean ingredients in the acute glycemic modulation after a complete meal by measuring blood glucose and insulin.


Eligibility criteria: Inclusion Criteria:

* Glycemia: 100-125mg/dL
* Both sexes
* Overweight BMI range (27-32)
* Age: 20-50 years old

Exclusion Criteria:

* Metabolic/Chronical disease
* Menopausal women
* Being pregnant, breastfeeding or wanting to have a baby
* Former obese with a history of yoyo effect
* Have been involved in a weight loss program in the past 12 months or subjected to weight reduction surgery
* Having started or quit smoking, having a high alcohol consumption
* Have in the past been in a long-term antibiotherapy (1 month or more) and/or a regular antibiotherapy in the past 12 months
* Allergy to olive, artichoke, black currant, grapefruit, grape, white kidney bean, olive, pomegranate.

Primary outcomes:
measure: Acute change in glycemia in response to a meal, by measuring glucose concentration in the blood at different time points
timeFrame: 8 hours
Secondary outcomes:
measure: Lipid profile evolution after a meal
timeFrame: 8 hours
measure: Oxxidative stress variation after a meal, measured by oxidized/reduced glutathione (GSH/GSSG)
timeFrame: 8 hours
measure: Acute change in insulinemia in response to a meal, by measuring insulin concentration in the blood at different time points
timeFrame: 8 hours
Other outcomes:
Locations:
city: Murcia
country: Spain
facility: UCAM
Study officials:
affiliation: UCAM
name: Pedro Alcaraz Ramon
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02597816: Role of Three Dimensional Ultrasound in the Diagnosis of Septate Uterus
Official title: Three Dimensional Trans-vaginal Ultrasound to Reevaluate Arcuate Uteri Diagnosed by Hystro-salpingography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Infertility
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2015-11-05
Enrollment: 38
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Congenital uterine anomalies are found in 8% of infertile women and 24.5% of infertile women with a history of recurrent miscarriage, with septate and sub-septate uterus being the most common anomalies in these women, Also, septate uterus is the commonest anomaly found in infertile women requiring assisted reproductive technology.

Published data showed improved Cumulative pregnancy rate and live birth rate, and a significant reduction in Miscarriage rate in In Vitro Fertilization women after hysteroscopic metroplasty of both small and large septate compared to non-operated women.

Investigators hypothesized that trans-vaginal three Dimensional Ultrasound will be superior to Hystro-salpingography for the differentiation between arcuate and septate uterus in infertile women scheduled for In Vitro Fertilization.


Eligibility criteria: Inclusion Criteria:

* women with primary infertility,
* an indication for IVF and
* Suspected arcuate or septate uterus diagnosis based on hysterosalpingography .

Exclusion Criteria:

* were confirmed uterine abnormality by prior office hysteroscopy

Primary outcomes:
measure: Number of patients diagnosed to have subseptate uterus by three dimensional ultrasound
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut university
Study officials:
References:
Clinical trial NCT06833216: Familial Breast Cancer in China
Official title: A Real-world Study of Familial Hereditary Breast Cancer in China
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Breast Carcinoma
Genetic Variation
Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sponsor class: OTHER
First posted: 2025-02-18
Enrollment: 500
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: From January 1, 2015 to December 31, 2024, a number of hospitals in China first diagnosed and treated breast cancer patients with genetic variants

Brief summary: This study is a retrospective descriptive study to collect clinical data (mainly including medical records and follow-up information, etc.) of breast cancer patients with genetic variation who were first diagnosed and treated in a number of hospitals in China during the period from January 1, 2015 to December 31, 2024, and to establish a retrospective cohort of familial hereditary breast cancer. To analyze the clinical features, diagnosis and treatment and survival prognosis of patients with familial hereditary breast cancer. To explore the main factors affecting clinical diagnosis and treatment and survival prognosis of patients


Eligibility criteria: Inclusion Criteria:

* Familial inherited breast cancer with genetic variants, including but not limited to mutations in the BRCA1, BRCA2, TP53, and PALB2 genes
* The patient had no major organ dysfunction
* ECOG score 0-1

Exclusion Criteria:

* There are serious dysfunction of vital organs (heart, liver, kidney)
* Patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years
* In other acute infectious disease or chronic infectious disease activity period
* A history of uncontrolled seizures, central nervous system disorders, or mental disorders

Primary outcomes:
measure: Overall survival rate
timeFrame: 5-year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Hospital, Chinese Academy of Medical Sciences
state: Beijing
Study officials:
References:
Clinical trial NCT00907816: Concurrent Electronic Order Entry Variation Reporting Impact on Ordering Behavior
Official title: Concurrent Electronic Order Entry Variation Reporting Impact on Ordering
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Behavior
Keywords: this study does not look at patient conditions
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2009-05-25
Enrollment: 72
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: PCPs at MGH

Brief summary: Display of information regarding utilization and quality to primary care physicians as they use our computer based system to order radiologic imaging (CT, MR, etc) will reduce unnecessary imaging.


Eligibility criteria: Inclusion Criteria:

* PCPs at MGH with patient panel \> 99 loyal patients

Exclusion Criteria:

* PCPs at MGH with patient panel \< 99 loyal patients

Primary outcomes:
measure: Health status adjusted utilization of imaging by each PCP in the intervention group, compared to themselves before intervention, and as a group to the control group
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Mass General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Jeffrey B. Weilburg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02600416: The CIRE Study (CItrate REcirculation Study)
Official title: Effects of AV Port Reversal in Citrate CVVH - The CIRE Study (CItrate REcirculation Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Kidney Injury
Lead sponsor: Ziekenhuis Oost-Limburg
Sponsor class: OTHER
First posted: 2015-11-09
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine the effects of AV port reversal (AVPR) on recirculation, clearance, post-filter ionized calcium and subsequently citrate dosing.

Detailed description: Rationale:

AV port reversal (AVPR) has been demonstrated to increase recirculation in venous catheters used in ICU for CVVH. The effects of this frequently used manoeuvre have not been described in the setting of CVVH using regional citrate anticoagulation.

Objective:

The aim of this study is to determine the effects of AVPR on recirculation, clearance, post-filter ionized calcium and subsequently citrate dosing.

Study design and methods:

Open trial studying the effect of AVPR in patients undergoing citrate CVVH. After measurement in standard catheter configuration, AVPR is performed after which effects on catheter recirculation, clearance, citrate dosing and post-filter ionized calcium (iCa) are monitored.

Sample sites:

Arterial line, arterial (pre-filter) port, postfilter port (after postdilution and calcium compensation), effluent sample. All flow rates to be noted.

Study population:

Twelve patients admitted to intensive care, requiring continuous renal replacement therapy (CRRT) for AKI. Patients are preferably anuric and have achieved good metabolic control under CVVH before inclusion in the study.

Eligibility criteria: Inclusion Criteria:

* Critically ill patients requiring CRRT for AKI (RIFLE criteria)
* Written informed consent from the patient or legal representative
* No AV port reversal had taken place before inclusion in the study
* Diuresis is minimal or the patient is anuric so that effects of changes in clearance as a consequence of diuresis are minimalized and do not influence study outcomes.
* The patient has undergone CVVH for a number of days, ensuring good metabolic control, so that possible short term loss of clearance as a consequence of AV port reversal has no detrimental effects.

Exclusion Criteria:

* pre-existing chronic renal insufficiency requiring dialysis
* chronic immunosuppression
* liver cirrhosis Child-Pugh C
* severe or shock-related hepatitis
* Pregnancy

Primary outcomes:
measure: change in citrate concentration in circuit after AV port reversal
timeFrame: 8 hours
measure: change in post-filter ionised Ca after AV port reversal
timeFrame: 8 hours
measure: change in clearance after AV port reversal
timeFrame: 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Genk
country: Belgium
facility: Ziekenhuis Oost Limburg
state: Limburg
Study officials:
affiliation: Ziekenhuis Oost-Limburg
name: Willem Boer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00560716: A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
Official title: A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Solid Tumors
Lead sponsor: Cyclacel Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2007-11-20
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.

Detailed description: Phase I study of an investigational cancer drug, CYC116, an Aurora kinase inhibitor, in patients with advanced solid tumors.

Eligibility criteria: Inclusion Criteria:

* Incurable advanced solid tumors that did not respond to conventional therapy or for which no effective therapy exists
* Age \>=18 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Life expectancy ≥ 3 months
* Evaluable disease
* Adequate bone marrow function
* Adequate renal function
* Adequate liver function
* At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities
* Able to swallow capsules
* At least 3 weeks from major surgery
* Agree to practice effective contraception

Exclusion Criteria:

* Previously untreated CNS metastasis or progressive CNS metastasis documented by MRI scan performed at 4 weeks or longer after the last treatment for CNS metastasis
* Currently receiving radiotherapy, biological therapy, or any other investigational agents
* Uncontrolled intercurrent illness
* Pregnant or lactating women
* Known to be HIV-positive
* Known active hepatitis B and/or hepatitis C infection

Primary outcomes:
measure: Safety and tolerability
timeFrame: over the course of study
Secondary outcomes:
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: Roswell Park Cancer Institute
state: New York
city: San Antonio
country: United States
facility: South Texas Accelerated Research Therapeutics
state: Texas
Study officials:
affiliation: Cyclacel Pharmaceuticals, Inc.
name: Judy H Chiao, MD
role: STUDY_DIRECTOR
References: